



1 22 August 2017
2 EMEA/HMPC/32116/2005 Rev.1
3 Committee on Herbal Medicinal Products (HMPC)

4 **Guideline on non-clinical documentation in applications**
5 **for marketing authorisation/registration of well-**
6 **established and traditional herbal medicinal products**
7 **Draft**

Draft agreed by Safety and Efficacy Drafting Group	11 January 2006
Draft adopted by HMPC for release for consultation	11 January 2006
End of consultation (deadline for comments)	15 April 2006
Re-discussion in Monograph and List Working Party (MLWP)	11 July 2006
Final adopted by HMPC	13 July 2006
Draft Revision 1 agreed by MLWP	01 June 2017
Draft Revision 1 adopted by HMPC for release for consultation	18 July 2017
End of consultation (deadline for comments)	30 November 2017

8

Comments should be provided using this [template](#). The completed comments form should be sent to hmpc.secretariat@ema.europa.eu

9

Keywords	Herbal medicinal products, non-clinical documentation, traditional use registration, marketing authorisation, European Union herbal monographs, European Union list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products, toxicity, genotoxicity, carcinogenicity, toxicity to reproduction
-----------------	---



10 Guideline on non-clinical documentation in applications
11 for marketing authorisation/registration of well-
12 established and traditional herbal medicinal products

13 **Table of contents**

14 **Executive summary 3**

15 **1. Introduction (background) 3**

16 **2. Scope..... 4**

17 **3. Legal basis 4**

18 **4. Non-clinical documentation 4**

19 4.1. General aspects 4

20 4.2. Genotoxicity 5

21 4.3. Carcinogenicity 6

22 4.4. Reproductive and developmental toxicity..... 6

23 **5. Non-clinical overview/expert report 7**

24

25 **Executive summary**

26 This guideline is intended to give advice for preparing and assessing applications for marketing
27 authorisation of well-established herbal medicinal products and for the registration of traditional herbal
28 medicinal products. It should be read in conjunction with the general requirements set out by Directive
29 2001/83/EC¹, in particular its Annex I, and general methodological requirements published by the
30 EMA.

31 *Revision 1* pertains to an update of the guideline after 10 years taking into account experiences gained
32 during the use of this guideline in national and European procedures and also during establishment of
33 EU herbal monographs. Other related guidelines not yet available at time of the first version have been
34 taken into consideration: Assessment of genotoxicity of herbal substances/preparations
35 (EMA/HMPC/107079/2007), Selection of test materials for genotoxicity testing for Traditional Herbal
36 Medicinal Products/Herbal Medicinal Products (EMA/HMPC/67644/2009), Limits of genotoxic
37 impurities" (CPMP/SWP/5199/02, EMA/CHMP/QWP/251344/2006), and ICH S2 (R1) on Genotoxicity
38 testing and data interpretation for pharmaceuticals intended for human use (CHMP/ICH/126642/2008).
39 Changes have been introduced accordingly in all sections of the guideline.

40 **1. Introduction (background)**

41 Herbal medicinal products are widely used within and outside the European Union². This wide use has
42 generated significant amount of bibliographical information relating to non-clinical safety. However,
43 published non-clinical tests for well-established and traditional herbal preparations are often
44 incomplete or not in accordance with today's state of the art. The complex composition of herbal
45 preparations presents an additional challenge. In order to obtain a better understanding of the inherent
46 risks with such products and to facilitate a continuous safety assessment, it is necessary to state the
47 minimum requirements for non-clinical data. Published toxicological information including scientifically
48 accepted monographs, well-presented clinical experience (with regard to the time and extent of use in
49 humans), epidemiological studies and data as well as post-marketing experience gained by wide
50 spread use in humans may contribute to the avoidance of unnecessary tests in animals (Directive
51 2001/83/EC, Annex I, Part II (1)b).

52 Directive 2001/83/EC allows the use of published literature in bibliographical applications for marketing
53 authorisation. The simplified registration of traditional herbal medicinal products will be based on the
54 expert report, bibliographical data and, if necessary, new tests. These legal provisions in no way relax
55 the requirements of proof of safety set out by the Annex to Directive 2001/83/EC. All aspects that are
56 relevant for the safety of the patient or consumer must be covered by appropriate literature or
57 appropriate reference to a review of literature, and must be addressed in the non-clinical summary of
58 an application for marketing authorisation or the expert report in a registration procedure, and
59 justification for the lack of data should be submitted. The specific character of bibliographic data on
60 herbal preparations used over a very long period of time, sometimes over centuries, requires additional
61 guidance for applicants and competent authorities on how to prepare and to assess such applications.

¹ Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code related to medicinal products for human use

² WHO: National Policy on Traditional medicines and Regulation of Herbal Medicines, WHO Geneva May 2005

62 **2. Scope**

63 This guideline provides guidance on the minimum requirements for non-clinical data for well-
64 established herbal medicinal products in bibliographical applications for marketing authorisations and
65 on the question which non-clinical safety aspects should be addressed in the expert report for the
66 simplified registration of traditional herbal medicinal products and which additional non-clinical safety
67 tests might be necessary to prove safety.

68 The guideline may also be used in the framework of assessment for establishment of a European Union
69 herbal monograph or an entry into the list of traditional herbal substances.

70 **3. Legal basis**

71 Article 10a of Directive 2001/83/EC makes it clear that the applicant shall not be required to provide
72 the results of pharmacological and toxicological tests if he can demonstrate by detailed reference to
73 published scientific literature presented in accordance with the provisions set out by Part II (1) of the
74 Annex I to Directive 2001/83/EC that the active substance(s) of the medicinal product have been in
75 well-established medicinal use within the European Union for at least ten years, with recognised
76 efficacy and an acceptable level of safety in terms of the conditions set out in Annex I.

77 Chapter 2a of Directive 2001/83/EC establishes specific provisions for the simplified registration of
78 traditional herbal medicinal products with a long-standing medicinal use of at least 30 years (including
79 at least 15 years within the European Union). According to Article 16c an application for registration
80 shall be accompanied by, among other items, a bibliographical review of safety data together with an
81 expert report (for more detailed information see "Guideline on the use of the CTD format in the
82 preparation of a registration application for traditional herbal medicinal products"
83 (EMA/HMPC/71049/2007 Rev. 2)³. Additional data necessary for assessing safety in accordance with
84 Annex I can be required by the competent authority. If an application for traditional-use registration
85 relates to an herbal substance, preparation or a combination thereof contained in the list referred to in
86 paragraph 1 of Art. 16f, the data specified in Article 16c(1)(b)(c) and (d) do not need to be provided.
87 Article 16e(1)(c) and (d) shall not apply. However, the Applicant should refer to aspects related to the
88 finished traditional herbal medicinal product, especially with regard to the excipients and their
89 influence on safety⁴.

90 **4. Non-clinical documentation**

91 **4.1. General aspects**

92 Any assessment must be based on a definition of the herbal substances / herbal preparation. Even if a
93 "full" quality dossier may not yet be available at the time when the non-clinical documentation is
94 prepared, the fundamental botanical and phytochemical characteristics of the herbal substance / herbal
95 preparations must be established. The presence of different herbal preparations and combinations of
96 herbal preparations that may have been used must be considered, and experience available in humans
97 should be documented for specific, single and well characterised herbal preparations. Data on extracts
98 produced from the same herbal substance with closely related extraction solvents such as different
99 ethanol/water mixtures or closely related DER may be used, if justified.

³ Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products (EMA/HMPC/71049/2007 Rev. 2)

⁴ Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches (EMA/CHMP/CVMP/JEG-3Rs/450091/2012)

100 The documentation should be based on a comprehensive literature search in scientific literature,
101 including handbooks and monographs specific to phytotherapy and traditional herbal medicine, and
102 searches in electronic databases. The search strategy and the results of the search must be
103 documented. If assessment reports of the HMPC supporting EU herbal monographs/ List entries for the
104 herbal substances / herbal preparations in question exist, those can be seen as starting points for a
105 comprehensive literature search starting from the given time of the literature search mentioned in the
106 assessment report. Non-clinical studies that do not comply with the current state of the art (e.g. GLP-
107 conformity) should be judged for credibility. A "blind" repetition of animal experiments should be
108 avoided.

109 In particular, it should be assessed whether the expected effects in animal studies would modify the
110 benefit/risk assessment and would have an impact on the granting of a marketing authorisation or
111 registration.

112 Many herbal preparations contained in well-established or traditional herbal medicinal products have an
113 accepted safety profile, which has been based on their long-term medicinal and/or food use. However,
114 in cases where a safety concern is recognised or suspected, non-clinical investigations may be needed.
115 The lack or the incompleteness of some specific non-clinical studies (e.g. genotoxicity studies or local
116 tolerance studies for the finished product) may also pose a safety concern. Such additional studies
117 should be provided to support a marketing authorisation or registration.

118 Where there is, in terms set out by the Directive 2001/83/EC, sufficient and well-documented
119 experience available in humans, testing of single dose and repeated dose toxicity, toxicokinetic studies,
120 immunotoxicity as well as local tolerance of traditional and well-established herbal
121 substances/preparations is not necessary. Likewise, pharmacological tests including primary and
122 secondary pharmacology, safety pharmacology and pharmacokinetics are not necessary, if there are
123 no reasons to expect a specific risk. The potential for pharmacokinetic interactions between the herbal
124 substance / preparation and other medicinal products must be discussed. The non-clinical overview /
125 expert report must address these aspects and give the rationale why the documented medical
126 experience justifies a safe use of the herbal substance / preparation, although such tests are not
127 available (Annex I, Part 2(1)c).

128 In general, the documented experience gathered during the long-standing use will be the main basis of
129 the non-clinical assessment of traditional and well-established herbal medicinal products. For this
130 reason, particular attention should be paid to effects that are difficult or even impossible to detect
131 clinically. These effects include toxicity to reproduction, genotoxicity and carcinogenicity. The relevance
132 of data on isolated constituents for the assessment of the herbal substance / preparation must be
133 discussed. Additional non-clinical testing of well-established and traditional herbal
134 substances/preparations would be necessary, if published literature is not available or insufficient. A
135 co-operative approach of stakeholders and interested parties is encouraged to investigate comparable
136 herbal preparations, e.g. extracts prepared from the same herbal substance with ethanol of different
137 strength and with comparable DERs⁵.

138 **4.2. Genotoxicity**

139 The genotoxic potential of herbal preparations should be assessed since pharmacovigilance and long-
140 standing use cannot be used as evidence for absence of genotoxic effects. Genotoxicity data are
141 available for many active substance(s), however, their quality is often inadequate for safety
142 assessment. When an adequate assessment cannot be made, further genotoxicity testing is required.

⁵ Guideline on selection of test materials for genotoxicity testing for traditional herbal medicinal products / herbal medicinal products (EMA/HMPC/67644/09)

143 A repetition of studies is only required in cases in which the relevance of the results is unclear or where
144 results provide reasons for suspicion. For such cases the following aspects may be considered:

145 *Structure-related concerns:* Known genotoxicity of single constituents (e. g. safrole), herbal substances
146 or herbal preparations must be taken into account, when closely-related active substances are
147 evaluated. It should be checked if genotoxicity is based on particular structural elements or attributed
148 to a group of constituents.

149 *Extrapolation of existing data:* If there are data on genotoxicity (positive or negative) for a herbal
150 substance or herbal preparation, they may be extrapolated to other herbal substances or herbal
151 preparations on a case-by-case basis. Data should be provided to compare the phytochemical profile or
152 explain the application of a concept of bracketing and matrixing. A comprehensive justification must be
153 given that differences are not expected to modify genotoxicity.

154 For substances in which the available genotoxicity data are insufficient it is recommended to start with
155 *in vitro* tests⁶. It is appropriate to assess genotoxicity initially in a bacterial reverse mutation test using
156 a test battery of different bacterial strains and metabolic activation.

157 The limitations of such a test (e.g. for testing mixtures of substances or antibiotic active substances)
158 should be taken into considerations in planning the test design and the test strategy⁷. Bacterial reverse
159 mutation test has been shown to detect relevant genetic changes and the majority of genotoxic rodent
160 carcinogens. Herbal preparations with negative results *in vitro* also exhibit negative results *in vivo* in
161 the majority of cases. In cases in which positive results *in vitro* are present, these are to be clarified by
162 way of appropriate investigations, mainly *in vivo*⁸. The complete testing strategy is comprehensively
163 displayed in other Guidelines of the HMPC^{5,6}.

164 **4.3. Carcinogenicity**

165 Carcinogenicity studies are not needed in cases where there is no suspicion for a carcinogenic
166 potential. However, carcinogenicity investigations do not necessarily have to be performed even if
167 there is a suspicion of a carcinogenic effect. Some points which should be considered in deciding the
168 need for carcinogenicity studies are:

- 169 • Is the suspicion based on results of genotoxicity studies and can it be clarified in further
170 genotoxicity studies, mainly *in vivo*?
- 171 • Is the suspicion based on a possible epi-genetic mechanism?
- 172 • Are the extent and the quality of the available scientific data (non-clinical, clinical,
173 epidemiological, post-marketing etc.) sufficient to refute the suspicion taking into account the
174 intended use?
- 175 • Are the extent and the quality of the available scientific data (non-clinical, clinical,
176 epidemiological, post-marketing etc.) sufficient to come to a positive benefit-risk assessment
177 taken into account the expected benefit from the herbal medicinal product?

178 **4.4. Reproductive and developmental toxicity**

179 Reproductive toxicological investigations regarding fertility are generally not necessary unless there is
180 cause for concern. Examples that would require a more detailed assessment include literature reports

⁶ Guideline on Assessment of genotoxicity of herbal substances/preparations (EMA/HMPC/107079/2007)

⁷ OECD (1997), Test No. 471: Bacterial Reverse Mutation Test

⁸ ICH S2 (R1) Genotoxicity testing and data interpretation for pharmaceuticals intended for human use (EMA/CHMP/ICH/126642/2008)

181 on hormone-like actions as well as other endocrine disruptions or a traditional use to influence fertility.
182 The relevance of such data for the herbal substance / herbal preparation must be discussed taking into
183 account e.g. phytochemical characteristics, posology, route of administration, duration of use etc.

184 The reproductive toxicological potential with regard to embryo-foetal and peri-post-natal development
185 should be assessed. Reproductive toxicity data are available for many old substances, however, these
186 data are often not reliable. A repetition of the tests is required in cases in which the significance of the
187 results is not clear and there are reasons for suspicion. If positive signals of reproductive toxicity (non-
188 clinical, clinical, epidemiological, post-marketing, traditional use) are identified in scientific literature,
189 further investigations of reproductive toxicity are necessary, unless justified by the applicant.

190 Reproductive toxicological tests in animals are not necessary if one of the following criteria is fulfilled:

- 191 • Results from post-marketing studies or epidemiological data of adequate power or post-
192 marketing safety studies are available.
- 193 • The assessment of the results of a systematic and comprehensive scientific literature search
194 and post-marketing experience does not identify a positive signal of reproductive toxicity and
195 the herbal medicinal product is not intended to be used during pregnancy and lactation.
- 196 • Results from investigations in pregnant women and neonates are present.
- 197 • The medicinal product is not intended to be used in women of childbearing potential.

198 The clinical overview should address women of childbearing potential and pregnancy. The assessment
199 of the information and the labelling should follow relevant EMA guidance.

200 **5. Non-clinical overview/expert report**

201 All relevant sections as required by Annex I of Directive 2001/83/EC must be addressed according to
202 the CTD format⁹. The expert is obliged to justify when non-clinical testing for the herbal preparation is
203 not performed. If an herbal medicinal product can be expected to be used together with other
204 medicinal products the potential of interactions has to be clarified. If the literature refers to an herbal
205 preparation other than the preparation intended for marketing, a detailed explanation must be
206 provided why the data can be used in spite of the existing differences.

207 The expert should discuss available published toxicological data on closely related herbal preparations,
208 different parts of the plant, data on related species of the same genus or plant family, where relevant.
209 If there are toxicological data on well-defined constituents of an herbal preparation, the expert should
210 discuss the relevance of these data for the safety assessment of the herbal preparation.

211 In the "Guideline on the assessment of genotoxicity of herbal substances/preparations"
212 (EMA/HMPC/107079/2007)⁶, there are also considerations for the risk assessment related to minor
213 constituents of herbal substances / herbal preparations.

214 The presentation of the data should demonstrate that the level of safety for the product is acceptable
215 taking into account the well-established / traditional use and the conditions set out by the summary of
216 product characteristics (SmPC). The relevance of deviations from the current state-of-the art
217 requirements, for the interpretation of study results should be discussed.

⁹ ICH - The Common Technical Document for the registration of pharmaceuticals for human use: Safety - M4S(R2)
Nonclinical overview and nonclinical summaries of Module 2 organisation of Module 4